# Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

Study · id `cardio:ct-nct01658501` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01658501](<https://clinicaltrials.gov/study/NCT01658501>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01658501

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 593 participants.

## Technical summary

Registry record NCT01658501. Randomized; quadruple masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2013-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 593 participants (enrolled count; ClinicalTrials.gov record NCT01658501, source copy `cardio:ctgov-nct01658501-2015-12-07`, retrieved 2026-10-26)
- Start date: 2012-07 (registry gives no type) (ClinicalTrials.gov record NCT01658501, source copy `cardio:ctgov-nct01658501-2015-12-07`, retrieved 2026-10-26)
- Primary completion: 2013-07 (actual) (ClinicalTrials.gov record NCT01658501, source copy `cardio:ctgov-nct01658501-2015-12-07`, retrieved 2026-10-26)
- Completion: 2013-07 (actual) (ClinicalTrials.gov record NCT01658501, source copy `cardio:ctgov-nct01658501-2015-12-07`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01658501, source copy `cardio:ctgov-nct01658501-2015-12-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01658501-2015-12-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): 50 mg PB1023
- Intervention (Drug): 70 mg PB1023
- Intervention (Drug): 100 mg PB1023
- Intervention (Drug): Placebo (0.9% Sodium Chloride)
- Intervention (Drug): Victoza®
- Intervention (Other): Diet and Exercise
- Intervention (Drug): Metformin
- Intervention (Drug): Sulfonylurea
- Intervention (Drug): Metformin and Sulfonylurea
- Lead sponsor: PhaseBio Pharmaceuticals Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 7fb11ce08415198ad81149726cb858c935b22fb3b9baf41a9a78df88487393d9
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
